Cambridge Healthtech Institute’s Tenth Annual
Novel Vaccines
Part Two: Emerging Technologies
August 25-26

Vaccine technology has evolved significantly in the last decade, profoundly changing the future of vaccine development. The urgent need to accelerate response time to emerging threats, make vaccines more widely available and ready for quick deployment, develop vaccines against difficult targets, and improve delivery systems for maximum potency have been the impetus behind many advances in vaccine technology. Synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and novel nanoparticle delivery systems are just a few of the realizations of this effort. CHI’s Tenth Annual Novel Vaccines: Emerging Technologies will present the latest advancements and applications of vaccine technology, and a look forward to overcoming current challenges. 

Day 1 | Day 2 | Download Brochure | Speaker Biographies
UD: Unpublished Data | CS: Case Study


Polly-Matzinger11:15 PLENARY KEYNOTE Dangerous Thoughts on Immunotherapy

Polly C. Matzinger, Ph.D. Senior Investigator, Ghost Lab, Laboratory of Immunogenetics, NAID/NIH

What we think influences what we do. If we continue to view the immune system through the old fashioned self-non-self model, the likelihood of finding truly effective immunotherapies is vanishingly small, whether those therapies are for autoimmunity, cancer or transplantation. I will delineate the different predictions from the various models of immunity and show how they influence how we approach immunotherapy.

12:15 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Session Break


1:30 Chairperson’s Opening Remarks

Kathryn Stephenson, M.D., MPH, Instructor, Medicine, Center for Virology and Vaccine Research/BIDMC, Harvard Medical School


Takashi K. Kishimoto, Ph.D., CSO, Selecta Biosciences

Selecta Biosciences is a clinical stage company that has developed a novel platform of Synthetic Vaccine Particles (SVP) to induce durable antigen-specific immune tolerance. Here we illustrate two potential applications of tolerogenic SVP for the treatment of autoimmune disease: 1) immune tolerance induction directed against a pathogenic autoantigen in experimental autoimmune encephalomyelitis, and 2) tolerance induction directed against an immunogenic biologic therapy (anti-TNFα monoclonal antibody) used in the treatment of arthritis.


2:20 Intra Lymph Node Injection Immunotherapy (ILNI™) Enables Superior Immunity

Anne K. Vallerga, Ph.D., Executive Vice President, Colby Pharmaceuticals

David A. Zarling, Ph.D., CEO, Colby Pharmaceuticals

ILNI™ enables superior immunity for tumor regression, allergy desensitization, and infectious disease. ILNI™ is straightforward, rapid, painless, safe, effective, durable, dose sparing, and reproducibly generates superior clinical immune responses via co-localization of antigens and cells within lymphoid organs and avoidance of suppression. ILNI™ allows higher vaccine antigen or cell doses to reach lymphatic cells and is safe and effective with either protein, peptide, RNA or DNA human cancer vaccines, as well as with autologous cell free tumor extracts, dendritic cells or other cells.

2:50 Optimizing Nucleotide Sequences for the Recovery of Universal Influenza Vaccine Candidate Viruses Expressing Engineered Hemagglutinins

Guadalupe Cortes-Garcia, Ph.D., Manager, Viral Immunology, Sanofi Pasteur

3:05 Refreshment Break in the Exhibit Hall with Poster Viewing


3:35 mRNA Vaccine Delivery Using Lipid Nanoparticles

Matthias A. Oberli, Ph.D., Postdoctoral Fellow, Langer Lab, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology


4:05 New Concepts in HIV Vaccine Development

Kathryn Stephenson, M.D., MPH, Instructor, Medicine, Center for Virology and Vaccine Research/BIDMC, Harvard Medical School

Prevention of HIV remains a public health priority, even in an era of widespread antiretroviral treatment. Experience with subunit vaccines and non-replicating vectors has been disappointing, with failure to show benefit in several efficacy trials. A trial of a canarypox vector plus gp120 showed modest protection in Thailand, but the effect was transient. This talk will focus on new approaches to HIV vaccine design and delivery, including mosaic HIV antigens and novel replicating vectors.

4:35 Intra Lymph Node Injection in Immunoprotective and Immunotherapeutic Infectious Disease Vaccine Development

David Zarling, Ph.D., CEO, Colby Pharmaceuticals

Reid Rubsamen, M.D., CEO, Flow Pharma

Proof of concept for Intra Lymph Node Injection (ILNI™) for infectious disease vaccination has been achieved for arenavirus, papillomavirus, simian or feline immunodeficiency virus, vaccinia virus, as well as staphylococcus and tuberculosis. We are developing ILNI™ and infectious disease vaccines for dose sparing, rapid onset, durable and superior immunity. Recent work on epitope targets favored by HIV controller patients describes a computation-driven vaccine applicable to HIV and other viral vaccines optimized for superior immunity. Colby and Flow Pharma are developing the vaccine technology platform integrating Intra Lymph Node Injection Immunoprotection and Immunotherapy (ILNI™).

5:05 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Dinner Short Course Registration*

Day 1 | Day 2 | Download Brochure | Speaker Biographies
UD: Unpublished Data | CS: Case Study


8:00 am Morning Coffee


8:25 Chairperson’s Opening Remarks

Daniel J. Wattendorf, M.D., Col., USAF, MC, Program Manager, Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA)

8:30 Novel Nucleic Acid-Based Immunoprophylaxis Technologies

Daniel_WattendorfDaniel J. Wattendorf, M.D., Col., USAF, MC, Program Manager, Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA)

DARPA is investing in novel immunoprophylaxis technologies, including RNA vaccines and DNA- and RNA-based passive gene transfer of antibodies. RNA-based vaccines encoding an antigen have been shown to enhance the robustness of the immune response. Additionally, RNA and DNA platforms for passive gene transfer of antibodies have the potential to bypass the adaptive immune response by establishing immediate but temporary protection. These platforms represent advancement in rapid design and manufacturing of immunoprophylaxis therapies for infectious disease prevention.

UD_Icon9:00 Development of Potent Influenza DNA Vaccines that Can Elicit Broad Cross-Protective Anti-Hemaggultination Responses against Diverse Viral Isolates Using Syncon® Technology

Jian Yan, Ph.D., Antigen Design Lead, Inovio Pharmaceuticals

An ideal Universal Influenza vaccine should be able to drive cross-protective immune responses against diverse viral isolates using a single vaccine formulation. However, the induction of cross-reactive neutralizing antibodies through vaccination has been historically difficult to achieve. Here, we showed that microconsensus-based HA DNA vaccines designed by SynCon® technology were able to generate cross-protective anti-hemaggultination responses against diverse H1N1 isolates. Furthermore, we extended this novel design to cover the newly emerged H7N9 viruses.

9:30 A Step-Change in Epitope Design Enables a Pipeline of Multi-Antigen DNA Tumor Vaccines

William Watt, Ph.D., CEO & Co-Founder, EpiThany, Inc.; University of Washington Tumor Vaccine Group

New cancer immunotherapies mark progress in our understanding of tumor biology and harnessing the immune system’s management of self. However, protein- and peptide-based vaccines are not yet consistently efficacious. Our work uncovers principles governing the genesis of T helper type-restrictive immunity to self-antigens elicited by vaccine epitopes, enabling the design of DNA vaccines to skew immunogenicity from tolerogenic Type II (Th2) to inflammatory Type I (Th1) T cells, and invigorating this cancer immunotherapeutic approach.

10:00 Nonviral Delivery of Self-Amplifying mRNA: A Novel Platform Technology

Antu Dey, Ph.D., Senior Scientist, Process & Product Development Leader, GlaxoSmithKline

10:15 Coffee Break in the Exhibit Hall with Poster Viewing


11:00 Statistical Phylogenetic Analysis of Post-Immunization Clonal Dynamics

Thomas B. Kepler, Ph.D., Professor, Microbiology, Professor, Mathematics and Statistics, Boston University School of Medicine

The character of the post-vaccination humoral response is determined by competition among B-cell clones and affinity maturation within them. Ig repertoire sequencing promises to substantially deepen our understanding of these processes and the interactions between them. I will describe statistical phylogenetic methods we have developed for partitioning repertoire data into clones and analyzing the inter- and intra-clonal dynamics and will illustrate their use in a study of repeated immunization to anthrax vaccine.

11:30 Whole Genome and Transcriptome Sequencing of Cotton Rat to Assist RSV Vaccine Research

I-Ming Wang, Ph.D., Principal Scientist, Genetics and Pharmacogenomics, Merck Research Labs

12:00 pm Immunogenomics of Non-Human Primates for Ig Repertoire Studies

Akshaya Ramesh, Kepler Lab, Genetics and Genomics, Boston University School of Medicine

12:30 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own


1:55 Chairperson’s Remarks

Deborah Higgins, Ph.D., Scientific Director, RSV Vaccine Project, PATH

2:00 Can Skin Vaccination Eliminate MNT in Developing Countries?

Ioanna Skountzou, M.D., Ph.D., Assistant Professor, Microbiology & Immunology, Emory University School of Medicine

2:30 Approaches to Estimate the Potential Impact of Novel Neiserial meningitidis Serogroup B Vaccines Prior to Implementation

Annaliesa_AndersonAnnaliesa Anderson, Ph.D., Senior Director, Vaccine Research and Early Development, Pfizer

Factor H binding protein (fHBP) is a meningococcal virulence factor that is a shared component of two recently licensed vaccines for the prevention of meningococcal serogroup B (MnB) disease. FHBP is ubiquitous to MnB isolates; however, there is antigenic diversity associated within the protein family. Approaches to estimate the impact of fHBP-based vaccines may have on MnB disease and carriage will be presented.

3:00 Development of a Human Vaccine and Therapy Post-Exposure Prophylaxis against Hendra and Nipah Viral Infections

Tim_FoutsTimothy Fouts, Ph.D., Senior Director, Virology, Profectus BioSciences

Nipah virus (NiV) and Hendra virus (HeV) are enveloped negative-sense RNA viruses causing systemic and fatal diseases in a variety of animal hosts and in humans. They are listed as Category C biothreat agents by the NIH and CDC and Overlap Select Agents by HHS and USDA. There is no approved human vaccine or therapeutic against either NiV or HeV. Profectus BioSciences, Inc. is developing HeV-sG, the ectodomain of HeV attachment glycoprotein, as a human vaccine and m102.4, an antiviral antibody, as a post-exposure therapy.

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing


4:15 Broad Immune Response Induced by Plant-Made Influenza VLP Vaccines

Sonia Trépanier, Ph.D., Senior Director, Clinical Studies, Medicago

Poor effectiveness reported for seasonal influenza vaccines reinforces the need for newer technologies such as Medicago’s plant-made virus-like particles (VLPs) to provide better vaccines that match circulating strains. Medicago’s VLP clinical trials showed immunogenicity responses meeting licensure criteria and induction of cross-reactive T cells, important in protection against antigenic drift. Plant-made influenza VLPs have the potential to provide better and broader immune response that could translate into better efficacy, especially in the elderly population.

4:45 Enveloped Virus-Like Particles – A Novel and Immunogenic Expression Platform

Adam_BuckleyAdam Buckley, MBA, Vice President, Business Development, VBI Vaccines, Inc.

In the past decade, virus-like particles have emerged as a powerful method for antigen presentation and a tremendous commercial success. VBI Vaccines, Inc. has created a next-generation antigen presentation platform capable of expressing envelope proteins within a lipid membrane – a true natural mimic for enveloped viruses. VBI will present data demonstrating the unique properties of this platform, including potency and commercial relevance of the platform by case study of its CMV vaccine.

5:15 Close of Novel Vaccines Part II: Emerging Technologies

Day 1 | Day 2 | Download Brochure | Speaker Biographies

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

2016 ImVacS-Immunization and Vaccine Summit

Download Brochure

2017 Final Agenda

Corporate Sponsors

Avanti Polar Lipids


Precision Nano Systems

Corporate Support Sponsor


View All Sponsors

View Media Partners

Re-Entering Antibacterial Discovery and Development Summit